Limits...
Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factor‑β/Smad pathway in rats.

Huang W, Li L, Tian X, Yan J, Yang X, Wang X, Liao G, Qiu G - Mol Med Rep (2014)

Bottom Line: It has been previously demonstrated that Astragalus and Paeoniae radix rubra extract (APE) had a protective effect against liver fibrosis in mice.Moreover, APE (2.6 and 5.2 g/kg) decreased the elevation of TGF‑β1, α‑SMA, collagen I and collagen III expression, inhibited Smad2/3 phosphorylation as well as elevated the expression of the TGF‑β1 inhibitor Smad7.The mechanism of action of APE is hypothesized to proceed via scavenging free radicals, decreasing TGF‑β1 levels and blocking of the TGF‑β/Smad signaling pathway.

View Article: PubMed Central - PubMed

Affiliation: Department of Scientific Research, Xi'an Medical College, Xi'an, Shaanxi 710061, P.R. China.

ABSTRACT
It has been previously demonstrated that Astragalus and Paeoniae radix rubra extract (APE) had a protective effect against liver fibrosis in mice. The present study aimed to investigate the hepatoprotective effect of APE on CCl4‑induced hepatic fibrosis in rats. Liver fibrosis was induced in male Sprague‑Dawley rats by intraperitoneal injection of 50% CCl4 twice a week for eight weeks. Organ coefficients, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), hexadecenoic acid (HA), laminin (LN), procollagen type III (PCIII), hydroxyproline (Hyp), glutathione (GSH‑Px), malondialdehyde (MDA), superoxide dismutase (SOD) and transforming growth factor β1 (TGF‑β1) levels were measured in rats with hepatic fibrosis. Histopathological changes in affected livers were studied using hematoxylin‑eosin and Masson's trichrome staining. The expression of transforming growth factor‑β/Smad pathway proteins, α‑smooth muscle actin (α‑SMA), collagen I and collagen III was observed in fibrotic livers using western blot analysis. The present study observed significant reductions in serum levels of AST, ALT, HA, LN, PCIII and Hyp in APE‑treated (2.6 and 5.2 g/kg) rats, indicating the significant hepatoprotective effects of APE. Furthermore, the depletion of GSH‑Px and SOD, in addition to the accumulation of MDA in liver tissue was suppressed by APE (2.6 and 5.2 g/kg). Pathological assessment of CCl4‑induced fibrotic livers revealed a significant reduction of liver injury and development of hepatic fibrosis in rats treated with APE (2.6 and 5.2 g/kg). Moreover, APE (2.6 and 5.2 g/kg) decreased the elevation of TGF‑β1, α‑SMA, collagen I and collagen III expression, inhibited Smad2/3 phosphorylation as well as elevated the expression of the TGF‑β1 inhibitor Smad7. These results suggested that APE may protect against liver damage and inhibit the progression of CCl4‑induced hepatic fibrosis. The mechanism of action of APE is hypothesized to proceed via scavenging free radicals, decreasing TGF‑β1 levels and blocking of the TGF‑β/Smad signaling pathway.

Show MeSH

Related in: MedlinePlus

Effect of APE on production of TGF-β1 in livers of rats with hepatic fibrosis. (A) Western blot analysis indicated that APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 expression levels in serum. (B) ELISA assay demonstrated that APE treatment (2.6 and 5.2 g/kg) notably reduced the levels of TGF-β1 in serum. #P<0.05, TGF-β1 levels as compared to CCl4 control group; *P<0.05, compared to model group. APE, Astragalus and Paeoniae radix rubra extract; TGF-β1, transforming growth factor β1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4262501&req=5

f4-mmr-11-02-0805: Effect of APE on production of TGF-β1 in livers of rats with hepatic fibrosis. (A) Western blot analysis indicated that APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 expression levels in serum. (B) ELISA assay demonstrated that APE treatment (2.6 and 5.2 g/kg) notably reduced the levels of TGF-β1 in serum. #P<0.05, TGF-β1 levels as compared to CCl4 control group; *P<0.05, compared to model group. APE, Astragalus and Paeoniae radix rubra extract; TGF-β1, transforming growth factor β1.

Mentions: The production of TGF-β1 was investigated using western blot analysis and ELISA assay. As shown in Fig. 4A, western blot analysis revealed that levels of TGF-β1 in hepatic fibrosis tissue were significantly elevated when compared to those of the normal control group (P<0.05). In addition, APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 levels when compared to those of the CCl4-only control group (P<0.05). However, the low-dose APE group (1.3 g/kg) and colchicine (0.1 mg/kg) group showed no statistically significant differences to the CCl4-only control group. The ELISA assay also revealed that APE treatment (2.6 and 5.2 g/kg) reduced levels of TGF-β1 in serum (P<0.05) (Fig. 4B). These results indicated that high doses of APE (2.6 and 5.2 g/kg) have the capacity to mitigate increased levels of TGF-β1 in rats with CCl4-induced hepatic fibrosis.


Astragalus and Paeoniae radix rubra extract inhibits liver fibrosis by modulating the transforming growth factor‑β/Smad pathway in rats.

Huang W, Li L, Tian X, Yan J, Yang X, Wang X, Liao G, Qiu G - Mol Med Rep (2014)

Effect of APE on production of TGF-β1 in livers of rats with hepatic fibrosis. (A) Western blot analysis indicated that APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 expression levels in serum. (B) ELISA assay demonstrated that APE treatment (2.6 and 5.2 g/kg) notably reduced the levels of TGF-β1 in serum. #P<0.05, TGF-β1 levels as compared to CCl4 control group; *P<0.05, compared to model group. APE, Astragalus and Paeoniae radix rubra extract; TGF-β1, transforming growth factor β1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4262501&req=5

f4-mmr-11-02-0805: Effect of APE on production of TGF-β1 in livers of rats with hepatic fibrosis. (A) Western blot analysis indicated that APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 expression levels in serum. (B) ELISA assay demonstrated that APE treatment (2.6 and 5.2 g/kg) notably reduced the levels of TGF-β1 in serum. #P<0.05, TGF-β1 levels as compared to CCl4 control group; *P<0.05, compared to model group. APE, Astragalus and Paeoniae radix rubra extract; TGF-β1, transforming growth factor β1.
Mentions: The production of TGF-β1 was investigated using western blot analysis and ELISA assay. As shown in Fig. 4A, western blot analysis revealed that levels of TGF-β1 in hepatic fibrosis tissue were significantly elevated when compared to those of the normal control group (P<0.05). In addition, APE treatment (2.6 and 5.2 g/kg) significantly decreased TGF-β1 levels when compared to those of the CCl4-only control group (P<0.05). However, the low-dose APE group (1.3 g/kg) and colchicine (0.1 mg/kg) group showed no statistically significant differences to the CCl4-only control group. The ELISA assay also revealed that APE treatment (2.6 and 5.2 g/kg) reduced levels of TGF-β1 in serum (P<0.05) (Fig. 4B). These results indicated that high doses of APE (2.6 and 5.2 g/kg) have the capacity to mitigate increased levels of TGF-β1 in rats with CCl4-induced hepatic fibrosis.

Bottom Line: It has been previously demonstrated that Astragalus and Paeoniae radix rubra extract (APE) had a protective effect against liver fibrosis in mice.Moreover, APE (2.6 and 5.2 g/kg) decreased the elevation of TGF‑β1, α‑SMA, collagen I and collagen III expression, inhibited Smad2/3 phosphorylation as well as elevated the expression of the TGF‑β1 inhibitor Smad7.The mechanism of action of APE is hypothesized to proceed via scavenging free radicals, decreasing TGF‑β1 levels and blocking of the TGF‑β/Smad signaling pathway.

View Article: PubMed Central - PubMed

Affiliation: Department of Scientific Research, Xi'an Medical College, Xi'an, Shaanxi 710061, P.R. China.

ABSTRACT
It has been previously demonstrated that Astragalus and Paeoniae radix rubra extract (APE) had a protective effect against liver fibrosis in mice. The present study aimed to investigate the hepatoprotective effect of APE on CCl4‑induced hepatic fibrosis in rats. Liver fibrosis was induced in male Sprague‑Dawley rats by intraperitoneal injection of 50% CCl4 twice a week for eight weeks. Organ coefficients, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), hexadecenoic acid (HA), laminin (LN), procollagen type III (PCIII), hydroxyproline (Hyp), glutathione (GSH‑Px), malondialdehyde (MDA), superoxide dismutase (SOD) and transforming growth factor β1 (TGF‑β1) levels were measured in rats with hepatic fibrosis. Histopathological changes in affected livers were studied using hematoxylin‑eosin and Masson's trichrome staining. The expression of transforming growth factor‑β/Smad pathway proteins, α‑smooth muscle actin (α‑SMA), collagen I and collagen III was observed in fibrotic livers using western blot analysis. The present study observed significant reductions in serum levels of AST, ALT, HA, LN, PCIII and Hyp in APE‑treated (2.6 and 5.2 g/kg) rats, indicating the significant hepatoprotective effects of APE. Furthermore, the depletion of GSH‑Px and SOD, in addition to the accumulation of MDA in liver tissue was suppressed by APE (2.6 and 5.2 g/kg). Pathological assessment of CCl4‑induced fibrotic livers revealed a significant reduction of liver injury and development of hepatic fibrosis in rats treated with APE (2.6 and 5.2 g/kg). Moreover, APE (2.6 and 5.2 g/kg) decreased the elevation of TGF‑β1, α‑SMA, collagen I and collagen III expression, inhibited Smad2/3 phosphorylation as well as elevated the expression of the TGF‑β1 inhibitor Smad7. These results suggested that APE may protect against liver damage and inhibit the progression of CCl4‑induced hepatic fibrosis. The mechanism of action of APE is hypothesized to proceed via scavenging free radicals, decreasing TGF‑β1 levels and blocking of the TGF‑β/Smad signaling pathway.

Show MeSH
Related in: MedlinePlus